This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or ...

A NOVEL non-peptide glucagon-like peptide-1 receptor agonist pill is more effective for weight loss than oral semaglutide in patients with Type 2 diabetes, a 2026 Phase III trial ...

Study finds weight loss results drive continued Ozempic use despite nausea and other side effects, based on real world ...

Hospital trips tied to semaglutide—the active ingredient in Ozempic and Wegovy—are rare, but can be serious, a new study found Compounded versions of semaglutide could explain some of these visits, ...

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

SLIMMING pills made by leading companies behind the fat jabs have been put in a head-to-head trial. Orforglipron led to almost double the weight loss than semaglutide and was better at controlling ...

Medical researchers have discovered that semaglutide may reverse the debilitating tissue damage caused by osteoarthritis, the world's most common form of arthritis. The drug behind Ozempic and Wegovy ...

In a phase 3 clinical trial, once-daily orforglipron outperformed semaglutide tablets, the best-known oral version of the GLP ...

Orforglipron carried more side effects, however ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

Simon Spichak finished his MSc at University College Cork, where he studied the interactions between the microbes in the gut and the brain. He became interested in science communication during his ...